p53 codon 72 polymorphism and breast cancer risk: A meta-analysis

Hou, Jing; Jiang, Yuan; Tang, Wenru; Jia, Shuting

doi:10.3892/etm.2013.1019

Cited by 33 publications

(26 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this metaanalysis, we found that the Pro allele of p53 gene was associated with risk of breast cancer risk for Europeans and Africans when compared to Arg allele. This finding is consistent in part with a previous meta-analysis which investigated breast cancer risk in 41 cases unmatched control studies [50], but discordant with the finding reported by Hou et al 2013 [51], Zhuo et al [52] and Hao et al [53]. The difference between these results can be explained by the presence of heterogeneity between studies, and the mixture studies with age-matched and/or unmatched controls in their analysis.…”

Section: Discussionsupporting

confidence: 90%

TP53 p.Arg72Pro polymorphism and Breast Cancer Risk: A meta-analysis of case-control studies

Diakité¹,

Kassogue²,

Dolo³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background :The effect of the p.Arg72Pro variant of the P53 gene on the risk of developmentof breast cancer remains variable in populations. However, the use of strategiessuchas pooling age-matched controls with disease cases may provide a solid meta-analysis. Our goal was to perform a meta-analysis in order to assessthe association of p.Arg72Provariant of P53 gene with breast cancer risk. Methods : Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Age-matched case-control studies on breast cancer that have evaluated the genotype frequencies of the p.Arg72Pro of P53 gene were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot. Results : Twenty-one publications with cases age-matched controls including7841disease cases and 8876controls were evaluated in this meta-analysis. Overall, our results suggested that p.Arg72ProP53 was associated with a risk for breast cancer for the dominant model (OR= 1.09, 95% CI = 1.02-1.16; P= 0.01) and the additive model (OR= 1.09, 95% CI = 1.01-1.17; P= 0.03), but not in the recessive model (OR = 1.07, 95% CI = 0.97-1.16; P= 0.19). According to the ethnic group, allele Pro has been associated with breast cancer risk in Europeans for the dominant and additive models. Conclusions : This meta-analysis found a significant association between p.Arg72Pro in the P53 gene and the risk of breast cancer. Individuals carrying at least one Pro allele of the P53 gene are more likely to have breast cancer with dominant and additive models than individualsharboringthe Arg allele.

show abstract

Section: Discussionsupporting

confidence: 90%

TP53 p.Arg72Pro polymorphism and Breast Cancer Risk: A meta-analysis of case-control studies

Diakité¹,

Kassogue²,

Dolo³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Arg/Pro genotype has no effect on the risk of breast cancer which is in line with the results of many domestic studies, such as Doosti et al27 and foreign researches of Hou et al33…”

Section: Discussionsupporting

confidence: 86%

The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis

et al. 2016

View full text Add to dashboard Cite

BackgroundBreast cancer is the most common cancer among women in Iran and the world. Multiple environmental factors and genetic variations such as genetic polymorphisms are of its main causes. p53 gene plays an important role in conserving and sustaining the genome as a tumor suppressing gene. Change and polymorphism at codon 72 of p53 gene are correlated with increased risk of lung, mouth, endometrial, prostate, and colorectal cancers, and could be considered an indicator of susceptibility to breast cancer.MethodsTwelve studies (1,190 cases and 1,145 control studies with evaluation of three types of Arg/Arg, Arg/Pro, and Pro/Pro genotypes) have been conducted using keywords, such as polymorphism at codon 72, gene p53 polymorphisms, and the relation between polymorphisms and breast cancer, from databases in Iran, including Magiran, Medlibe, Sid, and Iranmedex, as well as Latin databases such as PubMed, Google Scholar, Science Direct, and Scopus.ResultsThe OR for Arg/Arg is 1.58 (95% CI: 2.45 to 1.01), the OR for Arg/Pro is 0.75 (95% CI: 1.10 to 0.51), and the OR for Pro/Pro is 0.62 (95% CI: 0.93 to 0.42). p53 gene polymorphism at codon 72 is statistically significant in Arg/Arg and Pro/Pro genotypes.ConclusionsArg/Arg genotype can be considered as a risk factor for breast cancer, and Pro/Pro genotype can be accounted for as a protective factor against breast cancer.

show abstract

“…Although in the present study, there was no association between this polymorphism, and early‐onset breast cancer risk, associations have been reported in specific populations [Hu et al., ]. Meta‐analyses have demonstrated that this variant is not linked to breast cancer risk; however, these studies have been met with criticism [He et al., ; Ma et al., ; Hou et al., ].…”

contrasting

confidence: 54%

Assessment ofTP53Polymorphisms andMDM2SNP309 in Premenopausal Breast Cancer Risk

et al. 2017

View full text Add to dashboard Cite

Germline polymorphic variants in cancer predisposition genes such as TP53 have been shown to impact the risk of premenopausal cancer. Accordingly, the aim of this study was to assess the spectrum of polymorphisms in TP53 and its negative regulatory gene, MDM2 (SNP309:T>G) in patients with premenopausal breast cancer. Our findings in a cohort of 40 female patients demonstrate no significant correlation between the studied polymorphisms and risk of premenopausal breast cancer. Although one polymorphism is found in high frequency in this cohort (rs1800372:A>G, 9.0%), it was not associated with the risk of developing cancer before the age of 35 years in an extended cohort of 1,420 breast cancer cases. Functional studies of the rs1800372:A>G polymorphic allele reveal that it does not affect p53 transactivation function. Further study of variants or mutations in other cancer susceptibility genes is warranted to refine our understanding of the germline contribution to premenopausal breast cancer susceptibility.

show abstract

p53 codon 72 polymorphism and breast cancer risk: A meta-analysis

Cited by 33 publications

References 65 publications

TP53 p.Arg72Pro polymorphism and Breast Cancer Risk: A meta-analysis of case-control studies

TP53 p.Arg72Pro polymorphism and Breast Cancer Risk: A meta-analysis of case-control studies

The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis

Assessment ofTP53Polymorphisms andMDM2SNP309 in Premenopausal Breast Cancer Risk

Contact Info

Product

Resources

About